US 12,234,477 B2
Scalable primate pluripotent stem cell aggregate suspension culture
Thomas C Schulz, Athens, GA (US)
Assigned to ViaCyte, Inc., San Diego, CA (US)
Filed by ViaCyte, Inc., San Diego, CA (US)
Filed on May 24, 2021, as Appl. No. 17/328,980.
Application 17/328,980 is a division of application No. 16/200,479, filed on Nov. 26, 2018, granted, now 11,015,170.
Application 14/552,390 is a division of application No. 13/672,688, filed on Nov. 8, 2012, granted, now 8,895,300, issued on Nov. 25, 2014.
Application 16/200,479 is a continuation of application No. 14/552,390, filed on Nov. 24, 2014, granted, now 10,138,463, issued on Nov. 27, 2018.
Application 13/672,688 is a continuation in part of application No. 13/220,590, filed on Aug. 29, 2011, granted, now 8,445,273, issued on May 21, 2013.
Application 13/220,590 is a continuation of application No. 12/264,760, filed on Nov. 4, 2008, granted, now 8,008,075, issued on Aug. 30, 2011.
Prior Publication US 2021/0324329 A1, Oct. 21, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C12N 5/0735 (2010.01); C12M 3/04 (2006.01); C12N 5/071 (2010.01); C12N 5/073 (2010.01)
CPC C12N 5/0606 (2013.01) [C12M 27/12 (2013.01); C12N 5/0603 (2013.01); C12N 5/0676 (2013.01); C12N 2501/105 (2013.01); C12N 2501/11 (2013.01); C12N 2501/115 (2013.01); C12N 2501/117 (2013.01); C12N 2501/15 (2013.01); C12N 2501/16 (2013.01); C12N 2501/195 (2013.01); C12N 2501/41 (2013.01); C12N 2501/415 (2013.01); C12N 2501/998 (2013.01); C12N 2506/02 (2013.01); C12N 2509/00 (2013.01); C12N 2511/00 (2013.01)] 18 Claims
 
1. A bioreactor comprising primate pluripotent stem cell (pPSC) aggregates and pPSC-derived cell aggregates in suspension in a differentiation medium, wherein the pPSC-derived cell aggregates are produced in the bioreactor by agitating the pPSC aggregates at a shear rate of 5 to 500 sec−1, wherein the differentiation medium is substantially free of insulin, insulin-like growth factor-1 (IGF-1), or both insulin and IGF-1.